Compare PepsiCo, Inc. (PEP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? PepsiCo, Inc. trades at $127.25 (market cap $168.88B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and PepsiCo, Inc. pays a 4.78% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold PepsiCo, Inc. for 107 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| PEP | VRTX | |
|---|---|---|
Market Cap | $168.88B | $128.16B |
Volume | 13,263,972 | 806,603 |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $557.96 |
52-Week Low | $123.64 | $407.37 |
Typical Hold Time | 107 Days | 120 Days |
Enterprise Value | $211.38B | $122.29B |
Dividend Yield | 4.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $123.64, down 1.65% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS of $2.34 surpassing the $2.29 expectation. Revenue reached $93.93B in 2025, though net income margin dipped to 8.77%. Recent news highlights price cuts on snacks like Doritos to address consumer pushback on high prices.
The outlook is mixed: strong profitability metrics like a 51.59% ROE and a consensus analyst price target of $146.77 suggest upside potential, but competitive pressures and recent net margin compression pose risks. Institutional activity shows mixed signals with some firms increasing stakes while others reduce holdings.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
